Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.2 SEK | -1.54% | +2.56% | -18.88% |
04-25 | Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-27 | Enzymatica AB Announces Composition of Nomination Committee | CI |
Sales 2024 * | 6M 63.9M 473M | Sales 2025 * | 11.54M 123M 911M | Capitalization | 51.93M 554M 4.1B |
---|---|---|---|---|---|
Net income 2024 * | -4M -42.63M -316M | Net income 2025 * | -1M -10.66M -78.9M | EV / Sales 2024 * | 9.07 x |
Net Debt 2024 * | 2.46M 26.23M 194M | Net cash position 2025 * | 1.65M 17.55M 130M | EV / Sales 2025 * | 4.36 x |
P/E ratio 2024 * |
-12.5
x | P/E ratio 2025 * |
-21.4
x | Employees | 16 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 39.33% |
1 day | -1.54% | ||
1 week | +2.56% | ||
Current month | +5.61% | ||
1 month | -11.60% | ||
3 months | -1.39% | ||
6 months | -5.47% | ||
Current year | -18.88% |
Managers | Title | Age | Since |
---|---|---|---|
Ulf Thomas Blom
FOU | Founder | 59 | 31/12/06 |
Claus Egstrand
CEO | Chief Executive Officer | 63 | 17/07/17 |
Director of Finance/CFO | 55 | 31/12/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bengt Baron
CHM | Chairman | 62 | 18/12/16 |
Director/Board Member | 56 | 14/02/16 | |
Director/Board Member | 57 | 30/04/21 |
Date | Price | Change | Volume |
---|---|---|---|
15/05/24 | 3.2 | -1.54% | 63,370 |
14/05/24 | 3.25 | +3.17% | 95,036 |
13/05/24 | 3.15 | +0.32% | 49,176 |
10/05/24 | 3.14 | +0.64% | 83,579 |
08/05/24 | 3.12 | -3.70% | 90,279 |
Delayed Quote Nasdaq Stockholm, May 15, 2024 at 04:29 pm
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.88% | 51.93M | |
+31.37% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.83% | 239B | |
+9.93% | 211B | |
-6.95% | 203B | |
+10.77% | 171B | |
+0.10% | 163B |
- Stock Market
- Equities
- ENZY Stock